ESMO Asia Congress 2023

The addition of sotorasib to panitumumab significantly improves progression-free survival (PFS) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (CRC) compared with the investigator’s choice of standard-of-care (SoC) treatment, according to the CodeBreaK 300 trial presented at ESMO Asia 2023.

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.

Adjuvant treatment with alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) better than platinum-based chemotherapy at 2 years in Asian patients with early-stage, completely resected ALK-positive non–small cell lung cancer (ALK+ NSCLC) in an exploratory analysis of the phase III ALINA trial.

Patients with advanced solid tumours who have been treated according to matched targetable genomic mutation exhibit significantly longer overall survival than those who received standard-of-care (SOC) treatment, according to a Philippines study presented at ESMO Asia 2023.

In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.

In a study presented at ESMO Asia 2023, tofacitinib, a rapidly acting JAK-STAT inhibitor with reported efficacy in the treatment of various autoimmune diseases, was effective for the management of difficult-to-treat immune-related adverse events (irAEs) and was well-tolerated in cancer patients, with only a few patients developing infectious events.